Medication Monitor



Generic Name (Trade Name—Company)
Notes
August 30, 2017

Adalimumab-adbm

(Cyltezo—Boehringer Ingelheim)
Second biosimilar of Humira is FDA approved

FDA has approved adalimumab-adbm (Cyltezo), a biosimilar of Abbvie's Humira, in a prefilled syringe for the treatment of multiple chronic inflammatory diseases, including moderate to severe active rheumatoid arthritis, moderate to severe polyarticular juvenile idiopathic arthritis, active psoriatic arthritis, active ankylosing spondylitis, moderate to severe active adult Crohn disease, moderate to severe active ulcerative colitis, and moderate to severe plaque psoriasis.

It is administered by S.C. injection (40 mg/0.8 mL).

Cyltezo is the second FDA-approved biosimilar of Humira, joining Amgen's adalimumab-atto (Amjevita), which was approved in September 2016.